Can-Fite posted a GAAP net loss of USD 4.6 million for the six months ended June 30, narrowing 5.54%.
Research and development expense climbed 13.86% to USD 3.45 million, due to accelerated Namodenoson and Piclidenoson program spending.
General and administrative costs fell 31.4% to USD 1.42 million on lower investor relations expense; revenue was flat at USD 202,000.
Cash, cash equivalents and short-term deposits totaled USD 7.03 million; September warrant exercises and inducement added about USD 4 million gross.
Pivotal Phase 3 psoriasis interim analysis results are expected in Q1 2027; blinded overall survival in Phase 3 liver cancer study appears longer than assumed.
CANF•
